Results 191 to 200 of about 19,192,428 (324)

A New Strategy to Design Reconfigurable Rivest–Shamir–Adleman (RSA) Accelerators

open access: yesInternational Journal of Circuit Theory and Applications, EarlyView.
A reconfigurable FPGA‐based RSA accelerator is proposed using compression‐based modular multipliers combined with pseudomoduli arithmetic. The approach maps modular exponentiation to low‐cost arithmetic domains and applies a correction stage, achieving significant improvements in delay, operating frequency, and delay–area efficiency compared with ...
Augusto C. B. Vassoler   +4 more
wiley   +1 more source

Association of Serum Uric Acid with Indices of Insulin Resistance: Proposal of a New Model with Reference to Gender Differences

open access: yesDiabetes, Metabolic Syndrome and Obesity
Renjiao Liu,1 Zhouhuiling Li,2 Yanju Zhang,2 Meiyang Du,2 Xincheng Wang,3 Shi Zhang,3 Chunjun Li1,3 1Graduate School, Tianjin Medical University, Tianjin, People’s Republic of China; 2Tianjin University of Traditional Chinese Medicine, Tianjin, People’s ...
Liu R   +6 more
doaj  

Multivariate linear regression to predict association of non‐invasive arterial stiffness with cardiovascular events

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1141-1150, April 2025.
Abstract Background Arterial stiffness is a crucial factor in determining an increase in systolic blood pressure and pulse pressure and can also predict the development of cardiovascular disease (CVD). The purpose of this study was to examine the relationship between arterial stiffness and future CVD.
Susan Darroudi   +10 more
wiley   +1 more source

The outcomes of electronic personal health records in patients with heart failure or coronary artery disease

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1464-1468, April 2025.
Abstract Background There are limited data on the efficacy of smartphone‐based personal health records (PHRs) in patients with cardiovascular disease. This study aimed to examine the processes, outcomes and challenges associated with the implementation of integrated PHRs in patients with heart failure (HF) or coronary artery disease (CAD). Methods This
Kotaro Nochioka   +16 more
wiley   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia   +2 more
wiley   +1 more source

Left ventricular function improvement during angiotensin receptor–neprilysin inhibitor treatment in a cohort of HFrEF/HFmrEF patients

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1151-1165, April 2025.
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller   +8 more
wiley   +1 more source

eGFR slope as predictor of mortality in heart failure patients

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1217-1226, April 2025.
Abstract Aims Heart failure (HF) leads to an imbalance between heart and kidney function, resulting in poor outcomes. However, the prognostic significance of the estimated glomerular filtration rate (eGFR) trajectory in HF patients remains unclear. We analysed electronic health records (EHRs) of real‐world HF patients, assessing eGFR trajectories and ...
Sofie Verstreken   +10 more
wiley   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen   +7 more
wiley   +1 more source

Causal correlations between inflammatory proteins and heart failure: A two‐sample Mendelian randomization analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1374-1385, April 2025.
Abstract Aims Inflammation plays a critical role in both the development and progression of heart failure (HF), which is a leading cause of morbidity and mortality worldwide. However, the causality between specific inflammation‐related proteins and HF risk remains unclear.
Xian‐Guan Zhu   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy